Flagship Pioneering’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-7,932,624
| Closed | -$31.1M | – | 9 |
|
|
2023
Q3 | $31.1M | Buy |
7,932,624
+5,411,255
| +215% | +$21.2M | 2.26% | 7 |
|
|
2023
Q2 | $8.19M | Buy |
2,521,369
+3
| +0% | +$10 | 0.37% | 8 |
|
|
2023
Q1 | $9.11M | Hold |
2,521,366
| – | – | 0.35% | 9 |
|
|
2022
Q4 | $81.2M | Hold |
2,521,366
| – | – | 2.59% | 5 |
|
|
2022
Q3 | $105M | Hold |
2,521,366
| – | – | 4.44% | 6 |
|
|
2022
Q2 | $106M | Buy |
2,521,366
+1,369,863
| +119% | +$57.8M | 4.01% | 4 |
|
|
2022
Q1 | $78.1M | Hold |
1,151,503
| – | – | 1.83% | 8 |
|
|
2021
Q4 | $140M | Hold |
1,151,503
| – | – | 2.16% | 6 |
|
|
2021
Q3 | $162M | Hold |
1,151,503
| – | – | 1.7% | 6 |
|
|
2021
Q2 | $316M | Hold |
1,151,503
| – | – | 4.04% | 5 |
|
|
2021
Q1 | $246M | Buy |
1,151,503
+6,500
| +0.6% | +$1.39M | 3.95% | 5 |
|
|
2020
Q4 | $277M | Hold |
1,145,003
| – | – | 5.04% | 5 |
|
|
2020
Q3 | $121M | Hold |
1,145,003
| – | – | 3.33% | 6 |
|
|
2020
Q2 | $112M | Buy |
1,145,003
+233,333
| +26% | +$22.9M | 3.26% | 5 |
|
|
2020
Q1 | $68.6M | Hold |
911,670
| – | – | 3.21% | 6 |
|
|
2019
Q4 | $74M | Hold |
911,670
| – | – | 4.14% | 6 |
|
|
2019
Q3 | $111M | Hold |
911,670
| – | – | 6.08% | 5 |
|
|
2019
Q2 | $164M | Hold |
911,670
| – | – | 7.09% | 5 |
|
|
2019
Q1 | $146M | Hold |
911,670
| – | – | 5.52% | 5 |
|
|
2018
Q4 | $237M | Hold |
911,670
| – | – | 11.58% | 3 |
|
|
2018
Q3 | $222M | Hold |
911,670
| – | – | 14.68% | 2 |
|
|
2018
Q2 | $215M | Buy |
+911,670
| New | +$215M | 41.21% | 1 |
|